Sjögren's syndrome antibody testing detects characteristic circulating autoantibodies such as anti-SSA/Ro and anti-SSB/La in blood samples to support the diagnosis and classification of Sjögren's syndrome, a chronic autoimmune disease affecting the exocrine glands. This technical article reviews the key antibody markers, sample requirements, laboratory detection methods, quality standards, and clinical applications of the testing. Performed in accredited clinical laboratories operating under ISO 15189 quality management systems, these immunoassays provide objective immunological evidence for rheumatologists, immunologists, and other clinicians.
Technical Overview
Sjögren's syndrome (SS) is a chronic, systemic autoimmune rheumatic disease characterized by focal lymphocytic infiltration of the exocrine glands, most commonly the lacrimal and salivary glands, leading to dry eye (keratoconjunctivitis sicca) and dry mouth (xerostomia). The disease may occur as primary Sjögren's syndrome (pSS) or as secondary SS associated with other connective tissue diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), or systemic sclerosis (SSc).
Circulating autoantibodies are an immunological hallmark of the disease. Anti-SSA/Ro antibodies are detected in approximately 50–70% of patients with pSS, while anti-SSB/La antibodies are found in approximately 30–50%. The 2016 American College of Rheumatology / European Alliance of Associations for Rheumatology (ACR/EULAR) classification criteria assign 3 of the 6 required weighted points to anti-SSA/Ro positivity, underscoring the central role of serological testing in the diagnostic work-up.
Antibody detection is performed using validated immunochemical platforms in clinical immunology laboratories. Accreditation to ISO 15189 (medical laboratories — requirements for quality and competence) and the use of in vitro diagnostic reagents manufactured under ISO 13485 quality management systems ensure the traceability, precision, and comparability of reported results.
Testing Samples
Serum
Serum is the standard specimen for Sjögren's syndrome antibody testing. Typically 2–5 mL of venous blood is collected into plain or serum-separator tubes, allowed to clot for 30–60 minutes at room temperature, and centrifuged to obtain a clear serum sample. Serum may be stored at 2–8 °C if tested within several days; for longer storage, aliquots should be frozen at −20 °C or below, and repeated freeze–thaw cycles should be avoided to preserve antibody reactivity.
Plasma
Some automated chemiluminescence and multiplex bead-based platforms accept lithium-heparin or EDTA plasma as an alternative matrix. The specimen type must be validated in the assay instructions for use, and results from different matrices should not be interchanged without documented equivalence.
Specimen Quality and Handling
- Grossly hemolyzed, lipemic, or icteric samples may interfere with optical signal readouts and should be recollected or reported with an appropriate comment.
- All specimens must be clearly labeled and handled as potentially infectious material in accordance with laboratory biosafety procedures.
- For suspected neonatal lupus or congenital heart block evaluation, maternal serum is tested, sometimes paired with neonatal samples for comparative interpretation.
- Sample transport should maintain integrity, with temperature-controlled conditions for specimens shipped to reference or accredited third-party laboratories.
Testing Items
A comprehensive Sjögren's syndrome serological work-up generally includes the following core and supplementary analytes:
- Antinuclear antibodies (ANA) — a first-line screening assay; fine-speckled nuclear immunofluorescence patterns are frequently associated with anti-SSA/SSB reactivity.
- Anti-SSA/Ro antibodies — including the anti-Ro60 and anti-Ro52 subtypes; the most sensitive serological marker and the only antibody incorporated into the ACR/EULAR classification criteria.
- Anti-SSB/La antibodies — a more disease-specific marker that typically co-occurs with anti-SSA/Ro; anti-SSB positivity without anti-SSA is uncommon.
- Rheumatoid factor (RF) — elevated in a substantial proportion of pSS patients and correlated with hypergammaglobulinemia and systemic involvement.
- Anti-α-fodrin antibodies — a complementary marker with incremental diagnostic value in seronegative patients, not part of formal classification criteria.
- Anti-muscarinic type 3 receptor (anti-M3R) antibodies — an emerging research marker related to glandular secretory dysfunction.
- Overlap and subset markers — anti-centromere, anti-mitochondrial M2, anti-dsDNA, anti-Sm, anti-U1-RNP, anti-Scl-70, and anti-cyclic citrullinated peptide antibodies to identify overlap syndromes or secondary SS.
- Supportive immunological tests — quantitative immunoglobulins (IgG, IgA, IgM), complement components C3 and C4, cryoglobulins, erythrocyte sedimentation rate, and serum protein electrophoresis for monoclonal gammopathy screening.
Testing Methods
Indirect Immunofluorescence (IIF)
ANA screening is traditionally performed on HEp-2 cell substrates. Anti-SSA/Ro and anti-SSB/La antibodies classically produce a fine-speckled nuclear fluorescence pattern. Results are reported as patterns and titers or as semi-quantitative indices on automated reading systems. IIF remains a widely recommended first-line screening approach due to its broad antigen coverage and high clinical sensitivity.
Enzyme-Linked Immunosorbent Assay (ELISA)
ELISA plates coated with purified or recombinant antigens (Ro60, Ro52, La) enable quantitative detection of specific antibodies against defined antigens. Calibration curves allow reporting of antibody concentrations or index values, and analytical sensitivity is generally higher than that of classic immunodiffusion techniques. ELISA is well suited to batch processing in medium- to high-volume laboratories.
Line and Dot Immunoblot Assays
Membrane-based immunoblot techniques immobilize multiple extractable nuclear antigens on a single strip, permitting simultaneous qualitative or semi-quantitative profiling of the relevant antibody spectrum. They are commonly used as second-line or confirmatory assays to define ANA specificity identified during screening and to differentiate anti-Ro52 from anti-Ro60 reactivity.
Chemiluminescence Immunoassay (CLIA)
Automated random-access chemiluminescence platforms using magnetic microparticle solid phases provide rapid turnaround, broad analytical range, and good intra-laboratory precision. Calibration traceability and electronic quality control make CLIA systems suitable for high-throughput clinical laboratories and urgent clinical settings.
Confirmatory and Reference Techniques
Double immunodiffusion (Ouchterlony) and counterimmunoelectrophoresis historically defined anti-SSA/SSB specificity with high diagnostic specificity but lower sensitivity and longer turnaround. They are occasionally retained for confirmatory testing and for comparability with earlier classification studies.
Quality Assurance and Standardization
- Testing should be performed in laboratories accredited to ISO 15189, with documented method validation and verification of analytical performance.
- Reagents and calibrators should originate from in vitro diagnostic manufacturers operating under ISO 13485 quality management systems.
- Each analytical run requires internal quality control materials at a minimum of two concentration levels, with defined acceptance criteria.
- Participation in external quality assessment or proficiency testing programs is essential for inter-laboratory comparability.
- Reference intervals and cut-offs must be verified on the local population, with standardized procedures for retesting and confirmatory testing of borderline results.
Applications
- Diagnosis and classification of primary Sjögren's syndrome according to the 2016 ACR/EULAR criteria, in which anti-SSA/Ro positivity contributes 3 of the required 6 weighted points.
- Differential diagnosis from SLE, rheumatoid arthritis, systemic sclerosis, IgG4-related disease, sarcoidosis, and chronic viral infections such as hepatitis C and HIV that can mimic sicca symptoms.
- Risk stratification — anti-Ro52 has been associated with cardiac conduction abnormalities and interstitial lung disease, while cryoglobulins, low complement, and hypergammaglobulinemia correlate with systemic manifestations and lymphoma risk.
- Obstetric management — identification of anti-SSA/Ro-positive pregnancies at risk of neonatal lupus and congenital heart block, guiding fetal echocardiographic surveillance and neonatal care planning.
- Therapeutic monitoring — serial immunoglobulin, complement, and rheumatoid factor measurements support assessment of disease activity and response to B-cell-targeted and immunosuppressive therapies.
- Clinical research and biobanking — standardized antibody profiling underpins patient stratification in epidemiological studies and clinical trials.
Serological results are interpreted together with complementary functional and histological assessments, including the Schirmer test, ocular staining score, unstimulated whole saliva flow rate, and labial salivary gland biopsy with a focus score of 1 or higher, to complete the classification work-up.
FAQ
What is Sjögren's syndrome antibody testing?
It is a group of blood-based immunoassays that detect autoantibodies associated with Sjögren's syndrome, principally anti-SSA/Ro and anti-SSB/La, together with ANA, rheumatoid factor, and supplementary markers. The results are combined with clinical and glandular function assessments to support diagnosis and classification.
Which antibody is most important for diagnosis?
Anti-SSA/Ro is the most sensitive marker and the only antibody included in the 2016 ACR/EULAR classification criteria. Anti-SSB/La provides additional specificity, so testing for both antibodies is recommended in the standard panel.
Does a positive anti-SSA/Ro result mean I have Sjögren's syndrome?
Not necessarily. Anti-SSA/Ro antibodies also occur in a significant proportion of patients with SLE, subacute cutaneous lupus, neonatal lupus, and in a small percentage of healthy individuals. Interpretation requires integration with symptoms, other laboratory findings, and glandular function tests under physician supervision.
What is the difference between anti-Ro52 and anti-Ro60?
They target two distinct proteins within the SSA/Ro antigen system. Anti-Ro60 is closely linked to classic SS and SLE serology, whereas isolated anti-Ro52 occurs in various autoimmune conditions including myositis and interstitial lung disease. Immunoblot assays can distinguish the two specificities.
Is fasting required before sample collection?
No. Antibody levels are not affected by fasting, and blood may be drawn at any time of day. However, grossly lipemic samples may be recollected to avoid optical interference in certain assay platforms.
How long does it take to receive results?
In routine clinical laboratories, results for ANA and single-antigen assays are typically available within 1–3 working days. Multiparameter immunoblot profiling may require additional time, and urgent chemiluminescence platforms can provide same-day turnaround where clinically required.
Can antibody titers be used to monitor disease activity?
Anti-SSA and anti-SSB antibody status tends to remain stable over time, so titers are not reliable activity biomarkers. Quantitative immunoglobulins, complement levels, cryoglobulins, and inflammatory markers are more informative for monitoring systemic activity and therapeutic response.